Highest-materiality recent filing
IDEXX Q1 beats: rev $1.14B (+14%), EPS $3.47 (+17%); raises FY guidance
Q1 revenue $1,141M (+14% as reported, +11% organic); EPS $3.47 (+17% as reported, +15% comparable).
IDEXX Q4 revenue $1.09B (+14% YoY), EPS $3.08 (+18%); guides FY26 rev $4.63B-$4.72B
Q4 revenue $1,091M (+14% as reported, +12% organic); EPS $3.08 (+18% as reported, +17% comparable).
Jay Mazelsky steps down as CEO effective May 12, 2026, transitions to Executive Chair; will retire from board in May 2027.
IDEXX Q3 revenue $1.1B (+13%), EPS $3.40 (+21%); raises FY2025 guidance
Revenue $1,105M (+13% reported, +12% organic); CAG Diagnostics recurring revenue +11% reported, +10% organic.
IDEXX Q2 EPS $3.63 (+49% reported); raises FY2025 revenue and EPS guidance
Q2 revenue $1,109M (+11% reported, +9% organic); CAG Diagnostics recurring revenue +9% reported, +7% organic.
IDEXX Q1 EPS $2.96 (+5%), rev $998M (+4%); raises FY25 revenue & EPS outlook
Q1 revenue $998M (+4% reported, +5% organic); EPS $2.96 (+5%, +7% comparable).
IDEXX Q4 revenue $954M (+6% YoY), EPS $2.62; guides 2025 rev $4.06-$4.17B, EPS $11.74-$12.24
Q4 revenue $954M (+6% reported and organic); CAG Diagnostics recurring revenue +7% organic.
IDEXX CFO Brian McKeon to retire June 2025; Andrew Emerson named successor effective March 1, 2025
McKeon will retire June 1, 2025; will step down as CFO March 1, 2025 and serve as Special Advisor until retirement.
IDEXX extends Ortho-Clinical Diagnostics supply agreement to 2044, revises pricing
IDEXX entered U.S. and European supply agreement amendments with Ortho-Clinical Diagnostics for dry slides used in veterinary chemistry analyzers.
IDEXX corrects FY24 comparable margin expansion to 30-60 bps (from 70-100 bps); Q3 EPS $2.80
Corrected 2024 comparable operating profit margin expansion to 30-60 bps from 70-100 bps (error in prior release).
IDEXX Q3 EPS $2.80, revenue $976M; cuts FY24 revenue guidance citing macro headwinds
Q3 revenue $976M (+7% reported, +6% organic); EPS $2.80 (+11% reported, +12% comparable).
IDEXX Q2 rev +6% to $1,004M; EPS $2.44; cuts FY guidance on litigation charge
Revenue $1,004M, +6% reported (+7% organic); CAG Diagnostics recurring +6% reported (+7% organic).
IDEXX Q1 revenue $964M (+7%), EPS $2.81; cuts 2024 revenue/EPS guidance on FX and visit slowdown
Q1 revenue $964M (+7% as reported and organic); EPS $2.81 (+10% reported, +9% comparable).
IDEXX Q4 revenue $902M (+9%); FY24 guides $3.93-4.04B, EPS $10.84-11.33
Q4 revenue $902M, up 9% reported and 8% organic; CAG Diagnostics recurring revenue +11% reported and +10% organic.
IDEXX Q3 revenue $916M (+9% reported); EPS $2.53; FY guidance updated to $3.635-$3.65B
Q3 revenue $916M (+9% reported, +8% organic) driven by CAG Diagnostics recurring revenue +10% reported (+9% organic).
IDEXX Q2 revenue $944M (+10% organic); EPS $2.67 (+71%); raises 2023 guidance
Q2 revenue $944M, +10% reported and organic; CAG Diagnostics recurring revenue +11% reported, +12% organic.
IDEXX Q1 revenue $900M (+8% reported, +10% organic); EPS $2.55; raises 2023 guidance
Q1 revenue $900M, up 8% reported, 10% organic; CAG Diagnostics recurring revenue up 9% reported, 12% organic.
IDEXX Q4 revenue +7% organic; EPS $2.05; FY23 guidance rev $3.59B-$3.69B, EPS $9.27-$9.75
Q4 revenue $829M (+3% reported, +7% organic); EPS $2.05 (+8% reported, +14% comparable).
IDEXX Q3 revenue $842M (+8% organic); EPS $2.15 (+13% comparable); updates FY2022 guidance
Q3 revenue $842M, +4% reported, +8% organic; CAG Diagnostics recurring revenue +5% reported, +9% organic.
IDEXX amends credit agreement, adds $250M term loan and SOFR conversion
Borrowed $250M incremental term loan on Oct 20, 2022 under amended credit facility.
IDEXX Q2 revenue $861M +4% reported; EPS $1.56 -33%; cuts FY2022 guidance
Revenue $861M, up 4% reported and 6.5% organic; CAG Diagnostics recurring revenue +4% reported, +7% organic.
IDEXX Q1 rev $837M (+8%); cuts FY22 EPS guidance to $8.11-$8.35 on vet capacity, forex, R&D charge
Q1 EPS $2.27 (-3% reported, +3% comparable); revenue $837M (+8% reported and organic).
IDEXX Q4 revenue $801M (+11%), full-year EPS $8.60 (+28%); guides 2022 revenue $3.5-$3.565B
Q4 revenue $801M, up 11% reported and 10.5% organic; CAG Diagnostics recurring revenue grew 13%.
IDEXX Q3 revenue $810M (+12%), EPS $2.03; raises FY2021 guidance to higher end
Q3 revenue $810M (+12% reported, +10% organic); EPS $2.03 (+20% reported, +12% comparable).
IDEXX Q2 revenue $826M (+30% reported, +25% organic); raises FY 2021 guidance
EPS of $2.34, up 36% as reported and 33% comparable basis.
On February 13, 2025, Dr. Asha Collins resigned from the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), effective immediately.
Brian P. McKeon, Executive Vice President, Chief Financial Officer and Treasurer of IDEXX Laboratories, Inc. (the “Company” or “IDEXX”) notified the Company that he will retire from IDEXX effective June 1, 2025.
the Board appointed Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group (“CAG”) Finance of the Company, as Executive Vice President, Chief Financial Officer and Treasurer of the Company, effective March 1, 2025.
On November 8, 2024, Jonathan W. Ayers, a member of the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), resigned from the Board and its finance committee, effective November 8, 2024.
On December 5, 2023, James F. Polewaczyk, Executive Vice President and Chief Commercial Officer of IDEXX Laboratories, Inc. (the “Company”), notified the Company of his intent to retire after more than 17 years of dedicated leadership and service, effective April 1, 2024.
On July 11, 2023 the board of directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”) elected Irene Chang Britt as an independent Class I Director
Max materiality 0.85 · Median 0.65 · Most common event earnings